相关实验视频

Updated: Jun 6, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

SNRPB和CEP290,预测扩散大B细胞淋巴瘤的预后,并与瘤免疫微环境相关

Jing Tang¹, Bo Lu¹, Ting Bin¹

¹Department of Haematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.

Annals of medicine

|December 3, 2024

概括

这项研究开发了一种用于扩散性大B细胞淋巴瘤 (DLBCL) 的预后基因特征,使用与雌激细胞结合相关的分子 (ERM). 包括SNRPB和CEP290在内的签名可以预测DLBCL中的患者结果和治疗反应.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的非霍奇金淋巴瘤.
与细胞效应相关的分子 (ERM) 与DLBCL进展,转移和临床结果有关.

研究的目的:

建立基于ERM的DLBCL的新型预后基因签名.
调查签名与免疫微环境的相关性,并预测治疗反应.

主要方法:

使用权重基因共同表达网络分析 (WGCNA) 和单变Cox分析来识别与DLBCL预后相关的关键基因和ERM.
差异表达分析和Venn图识别了常见的差异表达基因 (DEG).
使用LASSO回归构建了一个预后签名,其预后值在单细胞水平上得到了验证.

主要成果:

开发了一个14-ERM预后签名,包括SNRPB和CEP290,可以独立预测DLBCL预后.
该签名有效地区分了风险亚组,揭示了显著的免疫微环境变化.
该签名显示了预测化疗药物敏感性的潜力.

结论:

对DLBCL成功建立了一个包含SNRPB和CEP290的新型预后签名.
这个签名为DLBCL研究,预后和潜在指导治疗策略提供了有价值的工具.

关键词:

扩散性大B细胞淋巴瘤这种细胞的形成是Efferocytosis.预后签名预测签名风险子组的风险子组.瘤免疫微环境是一个微环境.

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...